Get the Stockscreener App
6.4651
3.44%
-0.2249
Aquestive Therapeutics Inc stock is traded at $6.4651, with a volume of 1.61M.
It is down -3.44% in the last 24 hours and up +32.38% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$6.69
Open:
$6.69
24h Volume:
1.61M
Relative Volume:
0.70
Market Cap:
$645.21M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-17.76
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
+11.38%
1M Performance:
+32.38%
6M Performance:
+166.94%
1Y Performance:
+37.44%
1-Day Range:
$6.395
$6.73
1-Week Range:
$5.78
$6.865
52-Week Range:
$2.12
$6.865
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
6.47 | 809.31M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
142.00 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.82 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.01 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.83 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
443.58 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? - Yahoo Finance
Is Aquestive Therapeutics Inc. reversing from oversold territoryJuly 2025 EndofMonth & Reliable Trade Execution Plans - newser.com
How to build a dashboard for Aquestive Therapeutics Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Aquestive Therapeutics (NASDAQ:AQST) - MarketBeat
JMP Securities Maintains Aquestive Therapeutics (AQST) Market Outperform Recommendation - Nasdaq
What high frequency data says about Aquestive Therapeutics Inc.July 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ - GlobeNewswire
Aquestive Therapeutics Shares Rise After Obtaining 2 New US Patents for Anaphylm Sublingual Film - MarketScreener
Aquestive Therapeutics Obtains 2 New US Patents for Anaphylm Sublingual Film - MarketScreener
Aquestive receives two new patents for oral anaphylaxis treatment - Investing.com India
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ - GlobeNewswire Inc.
Signal strength of Aquestive Therapeutics Inc. stock in tech scanners2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Why Aquestive Therapeutics Inc. stock is seen as undervaluedWeekly Profit Summary & Community Verified Watchlist Alerts - newser.com
Custom watchlist performance reports with Aquestive Therapeutics Inc.2025 Dividend Review & Free Expert Verified Stock Movement Alerts - newser.com
Statistical indicators supporting Aquestive Therapeutics Inc.’s strengthTrade Analysis Summary & Comprehensive Market Scan Insights - newser.com
Advanced analytics toolkit walkthrough for Aquestive Therapeutics Inc.Portfolio Profit Report & AI Forecast for Swing Trade Picks - newser.com
Aquestive Therapeutics Advances Anaphylm Clinical Development - TipRanks
Aquestive Therapeutics SVP sells $63,000 in shares By Investing.com - Investing.com Nigeria
Aquestive Therapeutics CEO Barber sells $551k in shares By Investing.com - Investing.com Canada
Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $550,798.29 in Stock - MarketBeat
Peter Boyd Sells 10,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Trading Down 5.3% After Insider Selling - MarketBeat
Aquestive Therapeutics SVP sells $63,000 in shares - Investing.com
Aquestive Therapeutics Hits New 52-Week High of $6.00, Up 105.43% - Markets Mojo
What drives Aquestive Therapeutics Inc stock priceAI-Driven Market Analysis & Master Stock Selection - earlytimes.in
Aquestive Therapeutics Hits New 52-Week High of $6.43 - Markets Mojo
Is Aquestive Therapeutics Inc a good long term investmentSmall Cap Stock Opportunities & Collaborate and Win Together - earlytimes.in
What analysts say about Aquestive Therapeutics Inc stockVolume Weighted Average Price & See Risk Factors Before Making Any Move - earlytimes.in
Published on: 2025-09-28 19:22:53 - earlytimes.in
Aquestive Therapeutics Sees Stock Surge Following FDA Approval News - timothysykes.com
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - MSN
Oppenheimer Raises Price Target for Aquestive Therapeutics Amid FDA Developments - StocksToTrade
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aquestive Therapeutics Inc Stock (AQST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Boyd Peter E. | See Remarks |
Sep 26 '25 |
Sale |
6.30 |
10,000 |
63,000 |
278,323 |
1.92%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):